Medicines Company The News

JP Morgan Chase Following on from a morning in which the threat of ruinous writedowns, which has hung like a Sword of Damocles over most financial issues in recent weeks, zeroed in on HSBC, afternoon trading ...

The term of art is "rifle shot": That's what you call it when Congress passes a provision to benefit just one person or company.

Ex Libris Group is pleased to announce that the Hesburgh Libraries of Notre Dame in conjunction with its colleagues in the Michiana - LAGUNA BEACH, Calif.-- --Victoria Skimboards, the world leading skimboard ...

Jun 20, 2008 - The Medicines Company today announced that data from two post-hoc analyses of the ECLIPSE trial showed that use of Cleviprex injectable emulsion to control blood pressure during cardiac surgery ...

FalconStor Software, Inc. , the provider of TOTALLY Open network storage solutions, today announced an expert - 06/17/2008 - 05:14 PM PAOLI, Pa.-- --AMETEK, Inc.

June 17, 2008--The Medicines Company today announced that Glyn R. Parkin has joined the Company as Senior Vice President, International Operations.

The Medicines Company is scheduled to present at The Seventh Annual Needham Biotechnology and Medical Technology Conference on June 12 - 06/05/2008 - 04:58 PM HARTFORD, Conn.-- --Travelers has mobilized its ...

Celgene International S rl announced that, following discussions with the European Medicines Agency and the EMEA's Committee for Medicinal Products for Human use , it has withdrawn its Marketing Authorization ...

Drug stocks slipped in afternoon action Wednesday as shares of Favrille Inc. continued their downward spiral in the wake of Tuesday's news that the company was discontinuing work on its lead drug candidate.

We are a pharmaceutical company committed to becoming a leading provider of innovative, cost effective acute care hospital products to the worldwide hospital marketplace.

May 28, 2008 - The Medicines Company announced receipt of a not approvable letter from the U.S. Food and Drug Administration on a supplemental New Drug Application for an additional dosing regimen for Angiomax ...

PARSIPPANY -- GVA Williams New Jersey was honored by the New Jersey Chapter of the National Association of Industrial and Office Properties on May 15 withits 2007 Economic Impact Deal of the Year Award.

“These data from the ACUITY trial are consistent with overall findings that show Angiomax alone is the preferred antithrombotic strategy in moderate and high risk ACS patients undergoing early invasive treatment.”

Main Category: Cardiovascular / Cardiology Also Included In: Clinical Trials / Drug Trials Article Date: 07 May 2008 The Medicines Company announced that the Journal of the American College of Cardiology ... via MediLexicon

In the pharma days of yore , drug approvals were bountiful -- and for some companies, they still are. via The Motley Fool

Posted Thu Apr 24, 01:40 pm ET Posted By: Jason Napodano, CFA The Medicines Company specializes in acute care hospital cardiology products. via Zacks Analyst Blog

Robyn Brown - " VP, IR Glenn Sblendorio - " EVP and CFO Clive Meanwell - " Chairman and CEO John Kelley - " President and COO Analysts Liana Moussatos - " Pacific Growth Equities Matt Duffy - " Black Diamond ... via The Biotech Stock Blog

“If they don't get the patent extension for Angiomax, I anticipate that they will continue to show good growth, but face generic competition. Other products they have will help offset some of that, but it will not be a good thing”

The Medicines Company got off to a better than expected start to the year, but its future may depend on its success in lobbying Washington to help it extend the patent on its only drug on the market. via Forbes.com

“We are honored to welcome Dr. Goundis as a key member of ANAVEX's senior management team and believe we will benefit enormously from his wealth of drug development experience”

Anavex Life Sciences Corp. today announced the appointment of Dr. Dimitri Goundis as Project Director of Clinical Development as the company prepares to enter human clinical trials with its lead Alzheimer's ... via M2.com